semaglutide oral cardiovascular indication 2025 news Long-Term SELECT Trial: Cuts Events by 20% beyond Weight Loss semaglutide oral cardiovascular indication 2025

Understanding the 'why' is your first step toward mastering the 'how' to make it stop

Code 6-2-38

Air Charity Network www.aircharitynetwork.org 877-621-7177 Provides travel to treatment centers

Patients who have repeated weight measurements might be the extremes of weight change.

Educational background: The semaglutide molecule was originally developed for type 2 diabetes and is sold under the brand names Ozempic (for diabetes) and Wegovy (used for chronic weight management)

For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs